Lantern Pharma Q2 Loss Narrows 25% as AI Spin-Off Takes Shape
LTRN has more than doubled off its 52-week low of $1.11.
Summary
Lantern Pharma reported Q2 2026 results with loss from operations down ~25% year over year, reflecting tighter spending, though the Q2 operating loss widened on warrant expenses tied to a higher stock price. The company also formalized Open Medicine AI as a separate subsidiary with board-approved licensing agreements, positioning it for outside funding and a potential future listing. FDA reviewed HARMONIC trial protocol amendments without objection, and the USPTO issued a Notice of Allowance for a patient-selection signature for LP-184. These developments follow the May registered direct financing and the June S-1 resale registration, adding operational clarity to a company with a going concern warning and limited cash runway. The AI spin-off could unlock separate valuation, but Lantern remains 100% owner for now.
Updates
· SEC 8-K — Cash, cash equivalents, and marketable securities were approximately $7.4 million as of June 30, 2026. Q2 loss from operations was approximately $3.5 million, down about 25% year over year.
At the time of this announcement, LTRN was trading at $2.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.6M. The 52-week trading range was $1.11 to $4.86. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.